Small molecule · Inhibitor of anaplastic lymphoma kinase (ALK) and ROS1 proto-oncogene receptor tyrosine kinase (ROS1) · developed by Pfizer
Lorlatinib is a kinase inhibitor that acts on ALK and ROS1 and shows in vitro activity against several other kinases, including TRK family members, TYK2 and FAK. It inhibits ALK phosphorylation, including forms carrying resistance mutations, and has antitumor activity in models with EML4-ALK fusions, including intracranial tumors. It is used in ALK-positive metastatic non-small cell lung cancer and is being studied in advanced malignancies, solid tumors, ovarian cancer and urothelial cancer.
Summary written with AI from the sources listed at the end of this page.
From the indications section of the FDA label (version of Jun 26, 2026). Read the full label for the exact wording, limitations and safety information.
Advanced MalignanciesNSCLCOvarian CancerSolid TumorsUrothelial Cancer
Updated Oct 25, 2026. Something wrong or missing? Report it on the PFE page.
See PFE's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
PFE catalysts and pipeline →